Plus Therapeutics presented positive data from the FORESEE trial showcasing the CNSide Cerebrospinal Fluid (CSF) Assay Platform at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting on November 22, 2024. The trial demonstrated the assay’s utility in diagnosing and guiding clinical decision-making for leptomeningeal metastases (LM).
The prospective FORESEE trial met its key primary and secondary endpoints. The CNSide CSF Assay influenced clinical management decisions in over 90% of LM cases, indicating its significant impact on patient care.
The assay demonstrated 2.8 times the diagnostic sensitivity compared to standard cytology, addressing a critical need for improved LM diagnosis. This enhanced sensitivity positions CNSide as a valuable tool for physicians.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.